Key clinical point: The daily step count increased noticeably after initiating treatment with anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) in adults with chronic migraine, with a positive association seen between the increase in daily steps and the treatment response to CGRP mAbs.
Major findings: The average number of steps per day increased from 4421 before initiation of anti-CGRP mAb treatment to 5241 at 3 months after initiation of treatment ( P = .039), reflecting a mean percentage increase of 21.3% (95% CI 0.5-42.1). There was a positive association between an increase in daily steps and a reduction in monthly migraine days (correlation coefficient 0.521; P = .013).
Study details: This single-center, cross-sectional, retrospective study included 22 patients with chronic migraine who were treated with anti-CGRP mAbs (erenumab or fremanezumab).
Disclosures: The study was supported by the Lundbeck Foundation. Several authors declared receiving grants, honoraria, or personal fees from or having other ties with various sources.
Source: Jantzen FT, Chaudhry BA, Younis S, et al. Average steps per day as marker of treatment response with anti-CGRP mAbs in adults with chronic migraine: A pilot study. Sci Rep. 2024;14:18068 (Aug 5). Doi: 10.1038/s41598-024-68915-5 Source